Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma by Agarwal, Abhishek et al.
Mediterr J Hematol Infect Dis 2012; 4; Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Case Reports
Bilateral  Pleural  Effusions  due  to  Pulmonary 




1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.
2Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA. 
Correspondence to: Abhishek Agarwal. 
Rock, Arkansas, USA 72205. Tel: 1-501
Competing interests: The authors have declared th
Published: January 25, 2012
Received: November 11, 2011
Accepted: December 19, 2011
Mediterr J Hematol Infect Dis 2012, 4(1): e201
This article is available from: http://www.mjhid.org/article/view/9648
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
(http://creativecommons.org/licenses/by/2.0
provided the original work is properly cited
Abstract. Multiple Myeloma is a hematologic malignancy of plasma cell origin. Pleural effusion 
may develop in the setting of myeloma due to various reasons but is extremely uncommon as a 
presenting  symptom. A  69-year
undetermined  etiology  after  extensive  work  up,  and  multiple  failed  pleurodesis.  Lung  biopsy 
revealed pulmonary amyloidosis and led to the diagnosis of multiple myeloma. Patient was started 
on chemotherapy but died within 6 weeks of his diagnosis due to multiorgan failure. Pulmonary 
amyloidosis should be suspected as a cause of intractable pleural effusions, even in patient who do 
not have evidence of lung involvement on imaging studies or typi
Pleural effusions due to amyloidosis are often refractory to treatment, and a high index of suspicion 
is required for early diagnosis and treatment.
Introduction. Though  a  pleural  effusion  occurs  in 
approximately 6% of patients with Multiple 
(MM) during the course of the disease, it is not usually 
a presenting sign.
1,2 We present a case of a 69
Caucasian man who presented with intractable bilateral 
pleural effusions for 2 years without a clear etiology 
despite extensive work up at other centers. Our patient 
did not have the typical features of MM such as bone 
lesions, hypercalcemia or renal failure at the time of 
diagnosis. During the course of his work up, he was 
noted to have pulmonary amyloidosis on a lung biopsy, 
and  further  investigations  led  to  an  unsuspected 
diagnosis  of  MM.  MM  should  be  considered  in  the
differential of intractable pleural effusions and testing 
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yeloma is a hematologic malignancy of plasma cell origin. Pleural effusion 
may develop in the setting of myeloma due to various reasons but is extremely uncommon as a 
year-old  Caucasian  man  presented  with  pleural  effusions  of 
undetermined  etiology  after  extensive  work  up,  and  multiple  failed  pleurodesis.  Lung  biopsy 
revealed pulmonary amyloidosis and led to the diagnosis of multiple myeloma. Patient was started 
chemotherapy but died within 6 weeks of his diagnosis due to multiorgan failure. Pulmonary 
amyloidosis should be suspected as a cause of intractable pleural effusions, even in patient who do 
not have evidence of lung involvement on imaging studies or typical features of multiple myeloma. 
Pleural effusions due to amyloidosis are often refractory to treatment, and a high index of suspicion 
is required for early diagnosis and treatment.
Though  a  pleural  effusion  occurs  in 
ultiple Myeloma 
(MM) during the course of the disease, it is not usually 
We present a case of a 69-year-old 
Caucasian man who presented with intractable bilateral 
pleural effusions for 2 years without a clear etiology 
despite extensive work up at other centers. Our patient 
did not have the typical features of MM such as bone 
esions, hypercalcemia or renal failure at the time of 
During the course of his work up, he was 
noted to have pulmonary amyloidosis on a lung biopsy, 
and  further  investigations  led  to  an  unsuspected 
diagnosis  of  MM.  MM  should  be  considered  in  the
differential of intractable pleural effusions and testing 
for paraproteins should be considered. Also, this case 
highlights  the  point  that  a  lung  biopsy  should  be 
considered  early in  the  work up  of  recurrent  pleural 
effusions when a diagnosis is not forth
investigations, even if the lung parenchymal appears to 
be uninvolved on imaging studies.
Case  report.  A  69-year-
recurrent bilateral pleural effusions of unclear etiology. 
He had undergone thoracocentesis more than
over  the  last  2  years  and  had  bilateral  pleurodesis 
multiple  times  without  success.  Pleural  fluid  studies 
and a pleural biopsy were negative for malignancy or 
infection. He had no history of chest trauma, thoracic 
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yeloma is a hematologic malignancy of plasma cell origin. Pleural effusion 
may develop in the setting of myeloma due to various reasons but is extremely uncommon as a 
old  Caucasian  man  presented  with  pleural  effusions  of 
undetermined  etiology  after  extensive  work  up,  and  multiple  failed  pleurodesis.  Lung  biopsy 
revealed pulmonary amyloidosis and led to the diagnosis of multiple myeloma. Patient was started 
chemotherapy but died within 6 weeks of his diagnosis due to multiorgan failure. Pulmonary 
amyloidosis should be suspected as a cause of intractable pleural effusions, even in patient who do 
cal features of multiple myeloma. 
Pleural effusions due to amyloidosis are often refractory to treatment, and a high index of suspicion 
for paraproteins should be considered. Also, this case 
highlights  the  point  that  a  lung  biopsy  should  be 
considered  early in  the  work up  of  recurrent  pleural 
effusions when a diagnosis is not forthcoming on usual 
investigations, even if the lung parenchymal appears to 
be uninvolved on imaging studies.
-old  man  presented  with 
recurrent bilateral pleural effusions of unclear etiology. 
He had undergone thoracocentesis more than 25 times 
over  the  last  2  years  and  had  bilateral  pleurodesis 
multiple  times  without  success.  Pleural  fluid  studies 
and a pleural biopsy were negative for malignancy or 
infection. He had no history of chest trauma, thoracic Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
surgery, tuberculosis, lymphoma, cancer or significant 
exposure  to  asbestos.  His  renal,  hepatic  and  cardiac 
function  had  been  normal.  He  had  smoked  one-half 
pack cigarettes a day for 40 years and quit a year ago. 
He  reported  a  chronic  cough,  exertional  dyspnea, 
severe anorexia and weight loss of 30 kilograms in last 
3 months. Due to his intractable pleural effusions of 
undetermined  etiology,  he  was  admitted  for  a  lung 
biopsy and ligation of thoracic ducts.
The physical examination revealed a man with mild 
shortness  of  breath. He  had  generalized  edema, 
decreased  breath  sounds  over  the  lung  bases  and  a 
normal  cardiac  examination. He  was  afebrile  with 
normal respirations, a pulse of 86 beats per minute and 
blood pressure of 145/79 mm of Hg. White blood count 
was 8700 cells/mm
3, hemoglobin was 10 g/dL, serum 
creatinine was 1.1 mg/dL and serum calcium was 8.8 
mg/dL. Serum protein was 3.7 g/dL with albumin of 
2.7 g/dL. Liver function tests were normal. Urinalysis 
showed 30 mg/dL protein in a spot sample. C-reactive 
protein was elevated at 50 mg/L. Anemia work up was 
consistent with anemia of chronic disease with normal 
serum  B12  and  folate  levels.  A  chest  x-ray  showed 
bilateral  pleural  effusions.  Echocardiogram  showed 
normal  left  ventricular  ejection  fraction  of  60%  and 
there  were  no  features  of  cardiac  amyloidosis. 
Computed  tomography  of  the  chest  and  abdomen 
showed  multiple  calcified  mediastinal 
lymphadenopathy and pleural effusions with atelectasis 
of  the  lung bases,  but  no obvious  parenchymal lung 
lesions (Figure 1). 
Pleural fluid was exudative with a white count of 
212  cells/mm
3 with  88%  lymphocytes.  Fluid 
triglycerides  were  elevated  at  277  mg/dl,  lactate 
dehydrogenase  was  133  IU/L  and  fluid  protein  was 
2800  mg/dL.  The  fluid  was  negative  for  infection, 
plasma  cells  or  other  tumor  cells.  Histopathology  of 
biopsy   of   the   right   lung   revealed   pulmonary
Figure 1.  CT chest showing bilateral pleural effusions and clear 
lung parenchyma. 
Figure  2. Lung  biopsy  shows  hyaline  amyloid  deposits, 
predominantly in a perivascular pattern.
amyloidosis, mostly in a perivascular pattern, seen as 
hyaline  deposits  on  Hematoxylin  &  Eosin  stain 
(Figure  2).  Apple-green  birefringence  was  noted  on 
Congo-red  stain  under  polarized  light.  Mass 
spectroscopic  subtyping  revealed  AL-kappa  amyloid 
deposits. 
Serum protein electrophoresis showed total protein 
of 3.3 g/dL with albumin 1.6 g/dL but absence of M-
protein. Serum  and  urine  immunofixation  revealed 
presence of kappa free light chains. Serum free light 
chain analysis showed kappa free light chains of 47.2 
mg/dL (ref 0.33-1.95 mg/dL) and a kappa to lambda 
light chain ratio of 41.4 (ref 0.26-1.65). Urine protein 
electrophoresis showed 24-hour urine protein of 1201 
mg  with  M-protein  of  40%. A  bone  marrow  biopsy 
revealed 25% plasma cells comprised predominantly of 
kappa-expressing cells (Figure 3). A skeleton survey 
did not show any lytic or blastic lesions. 
Our  patient  met  the  diagnostic  criteria  for  MM 
based on bone marrow biopsy showing more than 10%
Figure 3. Bone marrow  biopsy shows abundant atypical  plasma 
cells with immature nucleiMediterr J Hematol Infect Dis 2012; 4: Open Journal System
plasma  cells,  monoclonal  protein  in  the  serum  and 
urine,  and  presence  of  a  myeloma-related  organ 
dysfunction in the form of anemia. The etiology of his 
intractable  effusion  was  felt  to  be  pulmonary 
amyloidosis  secondary  to  multiple  myeloma.  He  did 
not  have  features  of  amyloidosis  elsewhere  such  as 
cardiac failure, hepatomegaly, nephrotic syndrome and 
peripheral neuropathy. He was started on melphalan 
and bortezomib. His pleural effusions persisted despite 
thoracic  duct  ligation.  His  hospital  course  was 
complicated with acute renal failure, severe anasarca, 
deep  vein  thrombosis,  congestive  heart  failure, 
myocardial infarction and sepsis. The diagnosis of MM 
as  the  cause  of  his  intractable  pleural  effusion  was 
terminal as the patient expired within a few weeks of 
diagnosis. 
Discussion. MM accounts for 1% of all cancers and 
10% of all hematologic malignancies.
3 It mainly affects 
the  bone  marrow,  but  may  involve  other  organ-
systems.  Thoracic  manifestations  include  osseous 
lesions,  plasmocytoma,  pulmonary  infiltrates, 
mediastinal  lymphadenopathy  and  pleural  effusion.
1,4
In  patients  with  MM,  clinically  evident  primary 
amyloidosis develops in the course of disease in 10% 
to  15%  of  patients.
5 Pulmonary  amyloidosis  may 
present  as  pulmonary  nodules,  diffuse  interstitial 
amyloidosis, or pleural effusion associated with pleural 
amyloid deposition.
6
Pleural effusion in MM may occur due to several 
mechanisms:  namely,  an  involvement  of  the  pleural 
space  from adjacent skeletal or parenchymal tumors, 
mediastinal  lymph  node  infiltration  with  lymphatic 
obstruction, and pleural or pulmonary amyloidosis.
1,4,7
MM  can  be  complicated  by  nephrotic  syndrome, 
chronic  renal  failure,  restrictive  amyloid 
cardiomyopathy, and pulmonary embolism, which can 
all  result  in  pleural  effusion.  Direct  myeloma 
involvement  of  the  pleural  space  is  extremely  rare 
occurring  in  <  1%  of  cases.
8 Infectious  etiology  of 
effusion  is  common  due  to  associated 
hypogammaglobulinemia.  Large  persistent  pleural 
effusions refractory to diuretics and thoracentesis are 
more likely to be due to pleural amyloid infiltration.
9 In 
our case, the pleural fluid cytology did not reveal any 
myelomatous  cell,  and  the  recurrent  effusions  were 
secondary to pulmonary amyloidosis. 
Light  chain  myeloma  can  be  missed  on  serum 
electrophoresis,  as  in  our  case,  and  urine 
electrophoresis should always be done in the work up 
of MM. Pulmonary amyloidosis can be diagnosed by 
bronchoscopic lung  biopsy  with  reasonable  safety; 
although  the  bronchoscopist  should  be  prepared  to 
manage  hemorrhage  after  biopsy.
10 Pleural 
involvement can be diagnosed by presence of plasma 
cells in pleural fluid or a pleural biopsy. 
Pleural  effusions  due  to  amyloidosis  or 
myelomatous  involvement  of  the  pleural  space  are 
often  refractory  to  treatment  and  carry  a  poor 
prognosis.  Escalaton  of  testing  should  be  considered 
early in the work up of recurrent pleural effusion when 
diagnosis remains unclear on less invasive testing, as it 
can prevent delays in diagnosis and treatment. 
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